Skip to main content
OpenTrials
Completed

NCT Number: NCT02211898

Clinical Study of BNS003 on Swelling in Legs Due to Venous Reflux

To investigate the efficacy and safety of BNS003 on subjective symptoms such as sensation of heaviness/tiredness(dullness), tension, tingling, pain, fever or itching associated with swelling of calf and ankle due to disorder of leg venous reflux.

Completed

Looking for future studies?

Notify Me

Key information

Age range

20 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Manifestation of swelling falling into Class 1 according to Porter's classification
  • With more than 2 symptoms of "sensation of heaviness/tiredness (dullness)," "tension," "tingling," "pain," "fever" or "itching" and a total score of >=3 for severity by symptoms
  • Persons aged 20 years or older at the time of obtaining their informed consent and available for hospital visits. Both genders are acceptable
  • Persons who have consented to participating in the study in written form with good understanding of the objective of the study, the methods, and notices for the study period

Exclusion criteria

  • Persons with edema not due to venous diseases of the legs (e.g., lymphedema, latent cardiac or renal insufficiency, etc.)
  • Persons with peripheral arterial diseases
  • Persons with acute phlebitis, venous ulcer, congenital vascular anomaly, or Behcet's Syndrome
  • Persons with "moderate" or "severe" renal, hepatic, cardiac or haematological disorder, or with a history of such disorder (Grade 3 or 4 in Common Toxicity Criteria (CTC))
  • Persons with diabetes mellitus (excluding those curable with dietary therapy), neuropathy, hyper-or hypocalcemia, or malignant tumors
  • Persons with drug or alcohol abuse
  • Persons with immobility
  • Persons with pulmonary embolism
  • Persons with hypersensitivity to drugs (particularly to the ingredients contained in the investigational drug)
  • Persons with clinical indication of requiring venous treatment such as physical application (use of elastic bandage and compression stockings) and phlebectomy (vein stripping surgery to remove vein affected with varicosis and valve insufficiency)
  • Persons who received venous sclerosing therapy within the last 4 weeks before starting this study
  • Persons who constantly use theophylline preparations, diuretics, cardiac glycosides
  • Persons who had changed to or initiated post-menopausal hormone replacement therapy within the last 2 months before starting this study
  • Persons unable to suspend the frequent use and exceeded dosage/administration of laxatives (more than 6 times) during the study period
  • Persons planned to undergo a surgery requiring systemic anesthesia during the study period
  • Women in pregnancy or nursing, or those who wish for a pregnancy during the study period
  • Persons who participated in another study within the last 3 months before starting this study, or who plan to participate in another study during the study period
  • Persons who were considered to be ineligible to be a subject for the trial by the investigator or sub-investigators

Treatment and study plan

BNS003

Drug

Primary outcomes

  1. Global improvement on a five point scale

    Time frame: week 12

    The degree of improvement was evaluated according to change of severity of each symptom at the time of enrollment (baseline) and in Week 12 after initiation of dosing (or at discontinuation)

  2. Number of patients with adverse drug reactions

    Time frame: up to week 12

Secondary outcomes

  1. Improvement per symptom on a five point scale

    Time frame: 12 weeks

  2. Change in circumference measurements of calf in centimetres

    Time frame: baseline, 12 weeks

  3. Change in circumference measurements of ankle in centimetres

    Time frame: baseline, 12 weeks

  4. Subject's impression on improvement on a five point scale

    Time frame: baseline, 12 weeks

  5. Number of patients with of adverse events

    Time frame: up to 12 weeks

Sponsors and collaborators

Lead sponsor

Boehringer Ingelheim

Industry

Registry information

Official study title

Clinical Study of BNS003 on Swelling Due to Disorder of Leg Venous Reflux

Important dates

Study start
2004
Primary completion
2005
First posted
Aug 8, 2014
Registry last updated
Aug 8, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.